Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral Ischemia Clear all
Completed Phase 1Phase 2 Interventional Results available

Remote Ischemic Preconditioning Prior to Vascular Surgery

NCT01558596
View directory record Official record
Conditions
Peripheral Arterial Disease, Vascular Surgery
Interventions
Preconditioning, Control
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional Results available

Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

NCT01870401
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Lutonix DCB, Uncoated PTA Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
33
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Bradenton, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional Results available

PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System

NCT03124875
View directory record Official record
Conditions
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia
Interventions
LimFlow System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
21 Years to 95 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Wyoming, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated Phase 4 Interventional Results available

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT00832572
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Houma, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional Results available

A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.

NCT05145439
View directory record Official record
Conditions
Diabetic Foot Ulcer, Peripheral Arterial Disease, Wound; Foot
Interventions
VibratoSleeve Therapeutic Ultrasound Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Results available

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03404180
View directory record Official record
Conditions
Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Peripheral nerve block, Intravenous Sedatives, Lateral femoral cutaneous nerve blocks, Obturator nerve blocks
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Recruiting Phase 3 Interventional

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

NCT04433572
View directory record Official record
Conditions
Peripheral Artery Disease, Critical Limb Ischemia
Interventions
Temsirolimus, Saline placebo
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Houma, Louisiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Early Phase 1 Interventional

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

NCT03424746
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease
Interventions
disodium EDTA
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

NCT00189540
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions
HGF plasmid, Placebo
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

NCT00696124
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
VM202 2 mg, VM202 4 mg, VM202 8 mg, VM202 16 mg
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
20 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational

Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease

NCT00293748
View directory record Official record
Conditions
Vascular Disease, Vascular Disease Risk
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated Not applicable Interventional Results available

Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia

NCT00869375
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Endovascular peripheral intervention
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

NCT00067041
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Remodulin (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
4
States / cities
Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 28, 2026, 5:07 PM EDT
Withdrawn No phase listed Observational

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

NCT04059536
View directory record Official record
Conditions
Chronic Total Occlusion, Atherosclerosis, Coronary Artery Disease, Peripheral Artery Disease
Interventions
Roxwood Anchoring Catheters, Acetylsalicylic Acid, Heparin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
25 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Gainesville, Florida • Hobart, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 28, 2026, 5:07 PM EDT
Active, not recruiting Not applicable Interventional

The Chocolate Touch Study

NCT02924857
View directory record Official record
Conditions
Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
Interventions
Chocolate Touch, Lutonix Drug Coated Balloon
Device
Lead sponsor
TriReme Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
15
States / cities
Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

NCT00498069
View directory record Official record
Conditions
Ischemia
Interventions
Harvest Smartprep2 BMAC System, SmartPReP2 BMAC System, placebo
Device · Biological
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

VEGF Gene Transfer for Critical Limb Ischemia

NCT00304837
View directory record Official record
Conditions
Critical Limb Ischemia, Ischemia, Leg Ulcer
Interventions
pVGI.1 (VEGF-2)
Genetic
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years and older
Timeline
Ends 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 28, 2026, 5:07 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Statistical Learning as a Novel Intervention for Cortical Blindness

NCT06578117
View directory record Official record
Conditions
Stroke, Ischemic, Hemianopia, Homonymous, Hemianopsia, Occipital Lobe Infarct, Visual Field Defect, Peripheral, Vision Loss Partial, Quadrantanopia, Stroke Hemorrhagic
Interventions
Vision Training and Learning Task
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Enrolling by invitation Not applicable Interventional

Pivotal Trial of the Boomerang Catheter for pDVA

NCT06311773
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
Boomerang Catheter
Device
Lead sponsor
Aveera Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
San Bernardino, California • Sylmar, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Not listed Phase 2 Interventional

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

NCT00385385
View directory record Official record
Conditions
Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
Interventions
Rifalazil
Drug
Lead sponsor
ActivBiotics
Industry
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Lansing, Michigan • Roslyn, New York • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2007 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational

Evaluation of Patients With Known or Suspected Heart Disease

NCT00001313
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 5:07 PM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

NCT04306471
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059657
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Sep 28, 2026, 5:07 PM EDT